Literature DB >> 15647447

Bone mineral density in patients with rheumatoid arthritis treated with infliximab.

M Vis, A E Voskuyl, G J Wolbink, B A C Dijkmans, W F Lems.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647447      PMCID: PMC1755334          DOI: 10.1136/ard.2003.017780

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

1.  Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.

Authors:  Seo Young Kim; Sebastian Schneeweiss; Jun Liu; Daniel H Solomon
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

Review 2.  Effects of anti-tumor necrosis factor α agents on bone.

Authors:  Vivian K Kawai; C Michael Stein; Daniel S Perrien; Marie R Griffin
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

3.  Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.

Authors:  Frederick Wolfe; Marcy B Bolster; Christopher M O'Connor; Kaleb Michaud; Kenneth W Lyles; Cathleen S Colón-Emeric
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

Review 4.  Biologic therapies and bone loss in rheumatoid arthritis.

Authors:  C A F Zerbini; P Clark; L Mendez-Sanchez; R M R Pereira; O D Messina; C R Uña; J D Adachi; W F Lems; C Cooper; N E Lane
Journal:  Osteoporos Int       Date:  2016-10-31       Impact factor: 4.507

5.  The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis.

Authors:  Jia-Feng Chen; Chung-Yuan Hsu; Shan-Fu Yu; Chi-Hua Ko; Wen-Chan Chiu; Han-Ming Lai; Ying-Chou Chen; Yu-Jih Su; Tien-Tsai Cheng
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

6.  Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.

Authors:  David Simon; Arnd Kleyer; Sara Bayat; Koray Tascilar; Eleni Kampylafka; Timo Meinderink; Louis Schuster; Ramona Petrov; Anna-Maria Liphardt; Juergen Rech; Georg Schett; Axel J Hueber
Journal:  Arthritis Res Ther       Date:  2019-07-03       Impact factor: 5.156

7.  Different Effects of Biologics on Systemic Bone Loss Protection in Rheumatoid Arthritis: An Interim Analysis of a Three-Year Longitudinal Cohort Study.

Authors:  Ming-Han Chen; Shan-Fu Yu; Jia-Feng Chen; Wei-Sheng Chen; The-Ling Liou; Chung-Tei Chou; Chung-Yuan Hsu; Han-Ming Lai; Ying-Chou Chen; Chang-Youh Tsai; Tien-Tsai Cheng
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

8.  Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.

Authors:  Hubert Marotte; Pierre Miossec
Journal:  Biologics       Date:  2008-12

Review 9.  Bone effects of biologic drugs in rheumatoid arthritis.

Authors:  Addolorata Corrado; Anna Neve; Nicola Maruotti; Francesco Paolo Cantatore
Journal:  Clin Dev Immunol       Date:  2013-06-20

Review 10.  Bone and TNF in rheumatoid arthritis: clinical implications.

Authors:  Maria Manara; Luigi Sinigaglia
Journal:  RMD Open       Date:  2015-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.